Clinical Activity of Emiltatug Ledadotin (Emi-Le), a B7-H4-Directed ADC, in Patients with TNBC who Received at Least One Prior Topoisomerase-1 Inhibitor (Topo-1) ADC
Initial Phase 1 Dose Escalation Data for Emi-Le (emiltatug ledadotin; XMT-1660)
Learnings from Translational and Clinical Development of Dolaflexin and Dolasynthen ADCs
The Impact of Scaffold, Linker, Homogeneity and Payload Selection on the Efficacy and Tolerability of Anti-Tubulin ADCs
Results From the Phase 1 Dose Escalation Study of XMT‑1592, a NaPi2b‑Directed Dolasynthen ADC
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug to Antibody Ratios
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer
April, 2022
Site Specific Dolasynthen ADCs Demonstrate Consistent Exposure Across a Wide Range of Drug-To-Antibody Ratios
October, 2021